
Emily Reeve<sup>1,2</sup>, <u>Nagham J Ailabouni</u><sup>1</sup>, Wade Thompson<sup>3</sup>, Alice Bourke<sup>4</sup>, Chloe Furst<sup>4</sup>, Janet McNeece<sup>4</sup>, Sarah Hilmer<sup>5</sup>; Presenter's e-mail: Nagham.Ailabouni@unisa.edu.au

1. Quality

We developed a decision aid for consumers to facilitate shared decision-making with their healthcare professional about continuing or stopping their Cholinesterase inhibitor (ChEI)



Design and methods:
Development involved defining
the purpose, scope and target
audience, and assembling a
steering group to review the
prototype draft's content and
format. It also involved
conducting one-on-one interviews
with healthcare professionals and
consumers.

Results: A steering group composed of clinicians and consumer representatives was assembled. The group reviewed the prototype and changes were made for further testing. One-onone interviews were conducted with 3 General Practitioners and 7 consumers (one person living with dementia and 6 carers). The research team synthesised the findings to complete two rounds of modification. Iterative changes to improve the content, format and structure of the decision aid were made.